Saturday 17 October 2026 Export AGIO’s income statement to Excel — free account

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024. In the quarter to June 2026, revenue grew 259.3%, EPS grew 12.4% and free cash flow grew 25.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

31.32 1.00 −3.09%

Follow AGIO

Alert me

Market cap: $1.9B
P/E: 0.0×
Fwd P/E: −4.6×
Dividend yield: —
F-score: 3/9
Altman Z: 8.12
Beneish M: −1.72
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.54

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	5	1	—	7	6	—	—	1	1	—	—

Insider Ownership 2.08%

Capital & Financial Ratios $m

Market Cap 1,930.00

Revenue 98.34

Net Income (411.29)

Free Cash Flow (365.25)

Net Debt (617.58)

Current Ratio 10.22

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.58)

P/S ratio 18.95

P/B ratio 1.82

Past 5Y EPS Growth —

This Y EPS Growth 19.31%

Next Y EPS Growth 34.93%

Next Y revenue growth 229.46%

Next 5Y EPS Growth 37.17%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 21.64%

10-year low 10-year high

P/B against its own 10 years 39.14%

10-year low 10-year high

EV/Sales against its own 10 years 19.31%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	777	894	854	618
Receivables	3	4	11	20
Inventory	19	28	33	30
Other	—	—	—	—
	834	966	942	718

	2023	2024	2025	Q'26
Payables	10	17	18	16
ST’ Debt	—	—	—	—
Other	—	—	—	—
	68	81	82	70

Compound Annual Growth %

	10y	5y	3y
Sales	(1.89%)	(14.45%)	55.97%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	13.21%	24.46%	2.72%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	45	—	—	—
’25	9	12	13	20	54
’24	8	9	9	11	36
’23	6	7	7	7	27
’22	1	6	4	4	14
’20	87	37	35	44	203
’19	30	26	26	35	118

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(119)	(57)	—	—	—
’25	(111)	(77)	(88)	(96)	(373)
’24	(100)	(73)	(84)	(133)	(390)
’23	(95)	(67)	(62)	(72)	(296)
’22	(98)	(74)	(71)	(66)	(309)
’21	(121)	(117)	(85)	(84)	(407)
’20	(105)	(68)	(68)	(49)	(291)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(120)	(59)	—	—	—
’25	(112)	(78)	(90)	(97)	(377)
’24	(100)	(73)	(85)	(134)	(391)
’23	(95)	(67)	(61)	(73)	(296)
’22	(101)	(76)	(71)	(65)	(313)
’21	(122)	(118)	(85)	(89)	(413)
’20	(110)	(72)	(73)	(50)	(305)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.69)	(1.69)	—	—	—
’25	(1.55)	(1.93)	(1.78)	(1.85)	(7.12)
’24	(1.45)	(1.69)	16.22	(1.74)	11.64
’23	(1.47)	(1.51)	(1.64)	(1.72)	(6.33)
’22	(1.74)	(1.68)	(1.49)	0.67	(4.23)
’21	26.95	(1.41)	(1.56)	(1.74)	26.55
’20	(0.59)	(1.31)	(1.43)	(1.41)	(4.74)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	33.50	39.24	41.63	28.36	27.77	29.21	16.75	19.80	20.96	22.24	Analyst estimates 2026–2028 Powerpack
	High	67.74	72.73	99.82	68.94	56.75	62.16	35.12	31.56	62.58	46.00
People
People	Employees	287	382	482	536	562	392	393	386	488	540
	Revenue/emp, $m	0.24	0.11	0.20	0.22	0.36	0.00	0.04	0.07	0.07	0.10
Income, $m
Income, $m	Revenue	70	43	94	118	203	—	14	27	36	54
	Gross margin, %	100.00	100.00	98.52	84.79	(9.24)	0.00	88.03	89.26	88.59	88.26
	EBT	(198)	(315)	(346)	(301)	(329)	(357)	(232)	(352)	718	(414)
	EBT margin, %	(283.97)	(731.60)	(366.61)	(255.62)	(162.06)	0.00	(1,627.82)	(1,312.63)	1,967.15	(765.89)
	Net income	(198)	(315)	(346)	(411)	(327)	1,605	(232)	(352)	674	(413)
	Depreciation	6	6	3	5	13	16	7	2	(9)	(2)
Per share, $
Per share, $	Revenue	1.79	0.92	1.64	1.97	2.95	0.00	0.26	0.48	0.64	0.93
	Earnings	(5.07)	(6.75)	(6.03)	(6.86)	(4.74)	26.55	(4.23)	(6.33)	11.86	(7.12)
	Cash flow	0.99	(6.12)	(5.30)	(6.18)	(4.21)	(6.74)	(5.65)	(5.32)	(6.86)	(6.43)
	Capex	(0.25)	(0.10)	(0.12)	(0.20)	(0.20)	(0.09)	(0.07)	0.01	(0.03)	(0.07)
	Free cash flow	0.73	(6.22)	(5.42)	(6.38)	(4.42)	(6.83)	(5.72)	(5.31)	(6.89)	(6.51)
	Book value	9.16	8.06	11.97	10.68	5.79	21.37	20.09	14.57	27.13	20.58
	Shares, m	39	47	57	60	69	60	55	56	57	58
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00	2.79	0.00
	P/S	24.20	64.81	28.05	24.30	14.71	—	105.92	47.37	51.15	29.21
	P/B	4.72	7.42	3.85	4.47	7.48	—	1.37	1.57	1.21	1.32
	EV/Sales	16.45	54.95	21.85	19.51	11.90	—	50.95	18.41	26.67	13.40
	EV/FCF	40.13	(8.15)	(6.62)	(6.01)	(7.93)	—	(2.31)	(1.67)	(2.49)	(1.92)
Cash, $m
Cash, $m	Operating cash flow	39	(285)	(304)	(371)	(291)	(407)	(309)	(296)	(390)	(373)
	Capex	(10)	(5)	(7)	(12)	(14)	(6)	(4)	0	(2)	(4)
	Free cash flow	29	(290)	(311)	(383)	(305)	(413)	(313)	(296)	(391)	(377)
Balance, $m
Balance, $m	Working capital	471	350	520	519	542	1,004	770	766	884	860
	Total debt	—	—	—	1	0	0	72	—	—	—
	Net debt	(541)	(424)	(585)	(564)	(573)	(1,020)	(783)	(777)	(894)	(854)
	Shareholders’ equity	359	376	688	641	400	1,292	1,101	811	1,541	1,193
Returns, %
Returns, %	ROA	(38.20)	(51.02)	(46.99)	(47.05)	(37.55)	140.11	(17.32)	(32.36)	51.82	(27.89)
	ROIC	0.00	0.00	(221.60)	(258.99)	0.00	(86.88)	(76.54)	(717.72)	(41.11)	(87.12)
	ROE	(56.41)	(85.73)	(65.10)	(61.97)	(62.95)	189.74	(19.37)	(36.83)	57.29	(30.20)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IMNM Immunome, Inc.	$2.1B	— (loss-making)	— (loss-making)	+69.84% (above 0%: growing)	n/m	−26.96% (below 0%: shrinking)	100.00%	0.00%	Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR	$2.0B	— (loss-making)	— (loss-making)	−95.35% (below 0%: shrinking)	+198.85% (above 0%: growing)	+18.22% (above 0%: growing)	25.95%	(982.91%)	Compare
AGIO Agios Pharmaceuticals, Inc.	$1.9B	— (loss-making)	— (loss-making)	+259.25% (above 0%: growing)	n/m	+24.97% (above 0%: growing)	93.30%	(247.07%)
MLYS Mineralys Therapeutics, Inc.	$1.9B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
Median of peers	$1.9B	—	—	−34.34%	—	−20.72%	40.14%	(14.66%)

All 614 Biotechnology stocks →

Agios Pharmaceuticals, Inc. (AGIO) key facts

Concern: Agios Pharmaceuticals, Inc. reported a net loss of $412.8 million, or a loss of $7.12 per share, for fiscal 2025.
Strength: Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024.
Agios Pharmaceuticals, Inc. (AGIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AGIO traded at $31.32, a market capitalization of $1.9 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 18.9× sales.
Return on equity was −30.2% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 8.12 (safe zone) for fiscal 2025.